XBiotech Inc.: directors' dealings · United States · SEC (Form 4)

About XBiotech Inc.

XBiotech Inc. (NASDAQ: XBIT) is a U.S.-listed biotechnology company headquartered in Austin, Texas, United States. For French, Belgian and Swiss investors, it should be viewed as a clinical-stage biopharma company focused on the discovery, development and eventual commercialization of therapeutic antibodies derived from natural human immunity. The company describes itself as fully integrated, combining research, development and manufacturing capabilities on its Texas campus. XBiotech was incorporated in Canada on March 22, 2005, later building out its U.S. operating structure through XBiotech USA, Inc., incorporated in Delaware in 2007; its corporate headquarters are now in Austin, Texas. ([investors.xbiotech.com](https://investors.xbiotech.com/static-files/481a963d-2501-47fc-b160-054019e090bd)) Its investment case is centered on the True Human™ antibody platform. Rather than relying on traditional antibody engineering methods, XBiotech says it isolates antibodies directly from people with natural immunity to disease. That distinction is a core part of its scientific and commercial narrative, because the company believes this approach may support favorable tolerability and safety characteristics. XBiotech’s portfolio has historically spanned inflammation, immunology, oncology and infectious disease, with prior work in colorectal cancer, dermatology, staphylococcal infections and Ebola-related research. The company is still best understood as a pipeline-driven biotech rather than a product-rich commercial pharma business. ([xbiotech.com](https://www.xbiotech.com/?utm_source=openai)) Among the key assets, XBiotech highlights bermekimab, its anti-IL-1 alpha antibody, and Natrunix, another IL-1α-targeting program. Management has also emphasized that it retained rights to continue developing next-generation anti-IL-1α therapeutics after the 2019 acquisition of bermekimab by Janssen Biotech, which supports the strategic value of the platform and its intellectual property. In March 2026, the company announced that the U.S. Patent and Trademark Office granted three new patents covering True Human™ antibodies specific to interleukin-1 alpha, a meaningful reinforcement of its patent estate and a positive sign for long-term platform optionality. ([xbiotech.com](https://www.xbiotech.com/news/xbiotech-awarded-three-us-patents)) On the competitive front, XBiotech operates in a crowded field dominated by large pharmaceutical groups and numerous specialized biotech peers in immunology and oncology. As a smaller clinical-stage company, it must rely on scientific differentiation, robust clinical readouts, and strong IP protection to create value. One relative strength is its operational footprint: the company has a 48-acre campus in Austin with research, manufacturing and office infrastructure, and it announced plans in 2024 to construct an additional state-of-the-art R&D facility to support future development and possible commercialization efforts. That vertical integration can be advantageous if programs progress successfully. ([xbiotech.com](https://www.xbiotech.com/about-us)) Recent catalysts have focused on pipeline execution. In June 2024, XBiotech reported phase 1/2 data in advanced pancreatic cancer suggesting improved tolerability and encouraging efficacy trends for Natrunix combined with standard chemotherapy. Its investor materials also show that the company paused its rheumatology program in December 2024, indicating portfolio prioritization and capital discipline. For equity investors, XBiotech remains a high-risk/high-upside biotechnology story: the main value drivers are clinical data, patent expansion, and the ability to translate its True Human™ platform into partnering, licensing or eventual product revenues. ([investors.xbiotech.com](https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-results-randomized-double-blinded-phase-12-study/))